Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sagimet Biosciences (SGMT) is now covered by Rodman & Renshaw. They set a "buy" rating and a $28.00 price target on the stock.
Sagimet Biosciences (SGMT) had its "buy" rating reaffirmed by HC Wainwright. They now have a $29.00 price target on the stock.